Miguel Ángel Galve
Conseiller Juridique Général chez Cellerix SA
Profil
Miguel Ángel Galve is a professional who has worked as a Legal Director at Cellerix SA, and previously held the same position at Icron Group Holding Ltd.
and Genetrix SL.
He has an undergraduate degree from Universidad de Murcia and a graduate degree from Université Paris Dauphine-PSL.
Currently, he is working as a Legal Director at Cellerix SA.
Postes actifs de Miguel Ángel Galve
| Sociétés | Poste | Début |
|---|---|---|
Cellerix SA
 Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Conseiller Juridique Général | 25/11/2009 |
Anciens postes connus de Miguel Ángel Galve
| Sociétés | Poste | Fin |
|---|---|---|
Icron Group Holding Ltd.
 Icron Group Holding Ltd. Wireless TelecommunicationsCommunications Icron Group Holding Ltd. is the British parent company of Vectone Mobile, a Mobile Virtual Network Operator owned by the Mundio Group. The private company offers affordable international call solutions and is based in London, UK. It has subsidiaries in Poland, Ireland, and the United Kingdom. The company was founded in 1999. | Conseiller Juridique Général | - |
Genetrix SL
 Genetrix SL BiotechnologyHealth Technology Genetrix SL develops biotechnological solutions. It is comprised of technology and biomedicine companies in order to maximize the value of the Group. The company was founded in May 20, 2003 and is headquartered in Madrid, Spain. | Conseiller Juridique Général | - |
Formation de Miguel Ángel Galve
| Universidad de Murcia | Undergraduate Degree |
| Université Paris Dauphine-PSL | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Cellerix SA
Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Health Technology |
Genetrix SL
Genetrix SL BiotechnologyHealth Technology Genetrix SL develops biotechnological solutions. It is comprised of technology and biomedicine companies in order to maximize the value of the Group. The company was founded in May 20, 2003 and is headquartered in Madrid, Spain. | Health Technology |
Icron Group Holding Ltd.
Icron Group Holding Ltd. Wireless TelecommunicationsCommunications Icron Group Holding Ltd. is the British parent company of Vectone Mobile, a Mobile Virtual Network Operator owned by the Mundio Group. The private company offers affordable international call solutions and is based in London, UK. It has subsidiaries in Poland, Ireland, and the United Kingdom. The company was founded in 1999. | Communications |
